Overview: XDR Resistance Markers TestIntroduction: The XDR Resistance Markers Test tests for extensively drug-resistant bacteria to guide treatment for resistant infections, helping manage severe infections like tuberculosis. Affecting 1 in 100,000 people with resistant infections, XDR poses diagnostic challenges due to limited options. Following 2023 World Health Organization (WHO) guidelines, it uses PCR/culture for high accuracy, supporting bacteriology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in infectious disease.
Other Names: XDR Bacterial Test, Drug Resistance Assay.
FDA Status: FDA-approved test, meeting bacteriology standards for diagnostic reliability.
Historical Milestone: XDR testing began in the 2000s with research by Shah, who identified resistance genes. PCR advancements by Cepheid improved detection, surpassing earlier culture methods.
Purpose: Tests XDR resistance markers to diagnose resistant infections, guides alternative therapies, and evaluates patients with treatment failure, aiming to resolve infection.
Test Parameters: XDR resistance markers
Pretest Condition: Fresh sputum or swab sample required. Collect sputum or swab. Report history of chronic infections.
Specimen: Sputum (sterile container, 5-10 mL), Whole Blood (EDTA, 3-5 mL); Sputum or swab in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not recommended
Medical History: Document chronic infections or treatment failure. Include current medications or exposure history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., sepsis), and sample collection risks.
Procedural Considerations: Uses PCR/culture to detect markers, requiring labs with thermal cyclers or incubators. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample delay or contamination can affect results. Antibiotics may alter detection, requiring correlation.
Clinical Significance: Positive markers suggest XDR, guiding therapy. Early treatment might prevent spread, while untreated cases lead to death. Negative results may require other tests.
Specialist Consultation: Consult an infectious disease specialist for interpretation.
Additional Supporting Tests: Drug susceptibility testing, imaging, or sputum smear to confirm diagnosis.
Test Limitations: Specific to XDR; correlation with clinical status needed. False negatives possible with low bacterial load.
References: WHO Guidelines, 2023; Antimicrobial Agents and Chemotherapy, Shah NS, 2022.
